Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Pacira BioSciences's pe ratio was 104.2× on Nov 11, 2026, against 51.2× a year earlier. Over the last 5 years it ranged from 10.9× to 258.2×, with a median of 66.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 104.2× | +47.9 |
| 2025 | Dec 31, 2025 | 56.3× | +44.2 |
| 2024 | Oct 31, 2024 | 12.0× | −212.3 |
| 2023 | Dec 29, 2023 | 224.3× | +132.4 |
| 2022 | Dec 30, 2022 | 91.9× | +47.7 |
| 2021 | Dec 31, 2021 | 44.2× | +23.2 |
| 2020 | Dec 31, 2020 | 21.1× | −217.1 |
| 2019 | Oct 31, 2019 | 238.2× | – |
See a number that looks wrong?